Cathay Biotech (688065) H2 2024 earnings summary

Executive summary

• Revenue rose 39.84% year-over-year to ¥2,956.49 million, with net profit attributable to shareholders up 32.80% to ¥486.73 million.

• Significant growth driven by expansion in the long-chain dicarboxylic acid market and increased production capacity of new products.

• Continued investment in R&D for bio-based new materials and progress in downstream industry collaborations.

Financial highlights

• Operating profit increased 20.42% year-over-year to ¥547.04 million.

• Profit before tax rose 21.57% to ¥545.74 million.

• Net profit excluding non-recurring items surged 50.87% to ¥462.50 million.

• Basic EPS grew 33.33% to ¥0.84.

• Weighted average ROE improved by 1.02 percentage points to 4.33%.

Outlook and guidance

• Market expansion and product innovation expected to continue supporting revenue and profit growth.